FDA Action Update, June 2026: Acceptances, Clearances, and Alignments

• The World Health Organization (WHO) has added the first molecular diagnostic test for the Bundibugyo strain of Ebola virus to its Emergency Use Listing (EUL). • This risk-based procedure allows countries and procurement agencies to rapidly access quality-assured diagnostics before full regulatory approvals are finalized.

• Researchers have developed two new therapies for osteoarthritis, including a slow-release injectable drug system and engineered biomaterials delivered via arthroscopic procedure. • The biomaterial approach works by hardening in the joint to attract progenitor cells, which then regenerate damaged bone and cartilage.

• The FDA has issued reminders to over 2,200 medical product companies and researchers to comply with clinical trial results submission requirements. • Data shows that 29.6% of required trial results are currently missing from ClinicalTrials.gov, with negative outcomes frequently going unreported.

• The Trump administration has reduced funding for federal programs and agencies responsible for preventing, tracking, and responding to public health hazards. • These cuts target critical surveillance systems used to monitor disease trends and identify emerging pathogens.

• Recent health reports highlight the phenomenon of male marathoners "hitting the wall," exploring the physiological and psychological limits of endurance running. • New research and initiatives are focusing on the state of global mental health projections leading into 2026.

• The FDA experienced a slight slowdown in regulatory productivity during the first half of 2024 due to significant leadership instability and ongoing workforce attrition. • Under acting commissioner Kyle Diamantas, the agency has shifted toward a more open stance, particularly regarding rare disease therapies and accelerated approval applications.

• A new, shorter treatment regimen for rifampicin-resistant tuberculosis (RR-TB) has proven to be as effective as standard care. • Developed through research at the University of the Witwatersrand in South Africa, the protocol is notably applicable to children and pregnant women.

• The FDA approved six novel drugs for pediatric patients under 18 in 2026, including Copper histidinate (Zycubo) by Sentynl Therapeutics Inc. • Approved on January 12, 2026, Zycubo is indicated for the management of Menkes disease in children via subcutaneous formulation.

• A comprehensive review published in The Lancet concludes that mRNA vaccines are safe and highly effective in combating infectious diseases. • Led by researchers from the University of British Columbia and the London School of Hygiene & Tropical Medicine, the study analyzed data from billions of administered doses and clinical trials.

• National TV drug advertising spending rose 16% year-over-year in 2025, with the most significant growth occurring in the cancer, mental health, and weight loss categories. • Despite increased FDA enforcement regarding pharmaceutical advertising, industry experts believe sweeping rule changes are unlikely to occur in the near future.

• The World Health Organization (WHO) has launched the first-ever clinical trial to test treatments against the Ebola Bundibugyo virus in the Democratic Republic of the Congo (DRC). • The study will evaluate the efficacy of an antiviral drug and an antibody cocktail, with the first patient already enrolled in a trial that could include up to 1,200 participants.